autoimmunity psychosis
Conditions
Interventions
None listed
Sponsors
Universiteit Maastricht
Eligibility
Age
16 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Psychotic disorder, defined as one or more of the following symptoms: hallucinations, delusions, thought disorders or catatonia (standardized criteria of the CASH) - Psychotic disorder, defined as one or more of the following symptoms: hallucinations, delusions, thought disorders or catatonia (standardized criteria of the CASH) - Duration of disease shorter than 5 years - At least 16 years of age - Capacity to understand the purpose and details of the study in order to provide written informed consent. Alternatively, in the case of patients during a period of mental instability, the informed consent will be asked from family or a legal representative.
Exclusion criteria
Exclusion criteria: - Other severe brain disease which can interfere in the neurocognitive tests - Presence of other immune disorders with active treatment - Psychosis due to drug abuse
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome measure of this study is the prevalence of autoantibodies to specific neuronal surface ion channel/receptor proteins: NMDA-r, AMPA-r, GABAB-r, LGI1 and Caspr-2, in patients with an early onset stable psychotic disorder with or without autoimmune encephalitis. | — |
Secondary
| Measure | Time frame |
|---|---|
| a) Prediction of the presence of autoantibodies on the basis of clinical symptoms (by comparing clinical cognitive and neurological characteristics of patients with a psychotic disorder with or without an underlying autoimmune antibody). b) Identification of the effector functions of the autoantibodies (in vitro studies). Associate autoantibody effector functions with clinical characteristics. c) Study of the BBB integrity in a descriptive way and correlate these data with the clinical characteristics and the presence of autoantibodies. | — |
Countries
Netherlands
Outcome results
None listed